Annual Total Liabilities
$9.07 M
-$2.40 M-20.93%
December 31, 2023
Summary
- As of February 25, 2025, BCLI annual total liabilities is $9.07 million, with the most recent change of -$2.40 million (-20.93%) on December 31, 2023.
- During the last 3 years, BCLI annual total liabilities has fallen by -$6.73 million (-42.60%).
- BCLI annual total liabilities is now -51.67% below its all-time high of $18.76 million, reached on December 31, 2019.
Performance
BCLI Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$8.08 M
-$1.13 M-12.25%
September 30, 2024
Summary
- As of February 25, 2025, BCLI quarterly total liabilities is $8.08 million, with the most recent change of -$1.13 million (-12.25%) on September 30, 2024.
- Over the past year, BCLI quarterly total liabilities has stayed the same.
- BCLI quarterly total liabilities is now -56.91% below its all-time high of $18.76 million, reached on December 31, 2019.
Performance
BCLI Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
BCLI Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -20.9% | 0.0% |
| 3 y3 years | -42.6% | 0.0% |
| 5 y5 years | +45.9% | 0.0% |
BCLI Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -20.9% | at low | -36.4% | at low |
| 5 y | 5-year | -51.7% | at low | -56.9% | +20.4% |
| alltime | all time | -51.7% | >+9999.0% | -56.9% | >+9999.0% |
Brainstorm Cell Therapeutics Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $8.08 M(-12.2%) |
| Jun 2024 | - | $9.21 M(+3.5%) |
| Mar 2024 | - | $8.90 M(-1.9%) |
| Dec 2023 | $9.07 M(-20.9%) | $9.07 M(+9.7%) |
| Sep 2023 | - | $8.26 M(-14.2%) |
| Jun 2023 | - | $9.63 M(-24.3%) |
| Mar 2023 | - | $12.71 M(+10.9%) |
| Dec 2022 | $11.47 M(+15.4%) | $11.47 M(-3.4%) |
| Sep 2022 | - | $11.87 M(+6.8%) |
| Jun 2022 | - | $11.11 M(-1.7%) |
| Mar 2022 | - | $11.30 M(+13.8%) |
| Dec 2021 | $9.94 M(-37.1%) | $9.94 M(+3.4%) |
| Sep 2021 | - | $9.61 M(-20.3%) |
| Jun 2021 | - | $12.06 M(-2.5%) |
| Mar 2021 | - | $12.37 M(-21.7%) |
| Dec 2020 | $15.79 M(-15.8%) | $15.79 M(+135.3%) |
| Sep 2020 | - | $6.71 M(-28.6%) |
| Jun 2020 | - | $9.40 M(+3.7%) |
| Mar 2020 | - | $9.06 M(-51.7%) |
| Dec 2019 | $18.76 M(+201.9%) | $18.76 M(+28.6%) |
| Sep 2019 | - | $14.59 M(+9.0%) |
| Jun 2019 | - | $13.38 M(+16.1%) |
| Mar 2019 | - | $11.53 M(+85.5%) |
| Dec 2018 | $6.21 M(+12.1%) | $6.21 M(+63.9%) |
| Sep 2018 | - | $3.79 M(-53.5%) |
| Jun 2018 | - | $8.15 M(+46.0%) |
| Mar 2018 | - | $5.58 M(+0.6%) |
| Dec 2017 | $5.54 M(+541.6%) | $5.54 M(-9.7%) |
| Sep 2017 | - | $6.14 M(+763.6%) |
| Jun 2017 | - | $711.00 K(-9.9%) |
| Mar 2017 | - | $789.00 K(-8.7%) |
| Dec 2016 | $864.00 K(-70.7%) | $864.00 K(-27.7%) |
| Sep 2016 | - | $1.20 M(-6.8%) |
| Jun 2016 | - | $1.28 M(+3.2%) |
| Mar 2016 | - | $1.24 M(-57.9%) |
| Dec 2015 | $2.95 M(-8.8%) | $2.95 M(+4.0%) |
| Sep 2015 | - | $2.84 M(+12.4%) |
| Jun 2015 | - | $2.53 M(-7.3%) |
| Mar 2015 | - | $2.73 M(-15.8%) |
| Dec 2014 | $3.24 M(+62.9%) | $3.24 M(+29.5%) |
| Sep 2014 | - | $2.50 M(+29.9%) |
| Jun 2014 | - | $1.92 M(-42.3%) |
| Mar 2014 | - | $3.33 M(+67.7%) |
| Dec 2013 | $1.99 M | $1.99 M(+18.5%) |
| Sep 2013 | - | $1.68 M(+16.5%) |
| Jun 2013 | - | $1.44 M(+13.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2013 | - | $1.27 M(+9.9%) |
| Dec 2012 | $1.16 M(-8.0%) | $1.16 M(-8.4%) |
| Sep 2012 | - | $1.26 M(-21.0%) |
| Jun 2012 | - | $1.60 M(+11.5%) |
| Mar 2012 | - | $1.43 M(+14.0%) |
| Dec 2011 | $1.26 M(-18.9%) | $1.26 M(+38.2%) |
| Sep 2011 | - | $909.00 K(-33.6%) |
| Jun 2011 | - | $1.37 M(-21.1%) |
| Mar 2011 | - | $1.74 M(+12.2%) |
| Dec 2010 | $1.55 M(-38.1%) | $1.55 M(-22.8%) |
| Sep 2010 | - | $2.01 M(+3.1%) |
| Jun 2010 | - | $1.95 M(-2.2%) |
| Mar 2010 | - | $1.99 M(-20.4%) |
| Dec 2009 | $2.50 M(-15.3%) | $2.50 M(-25.9%) |
| Sep 2009 | - | $3.37 M(+8.2%) |
| Jun 2009 | - | $3.12 M(-0.2%) |
| Mar 2009 | - | $3.12 M(+5.8%) |
| Dec 2008 | $2.95 M(-15.9%) | $2.95 M(+3.9%) |
| Sep 2008 | - | $2.84 M(+4.5%) |
| Jun 2008 | - | $2.72 M(-23.0%) |
| Mar 2008 | - | $3.53 M(+0.5%) |
| Dec 2007 | $3.51 M(+38.3%) | $3.51 M(+12.2%) |
| Sep 2007 | - | $3.13 M(-15.5%) |
| Jun 2007 | - | $3.70 M(+16.2%) |
| Mar 2007 | - | $3.19 M(+48.4%) |
| Dec 2006 | $2.54 M(-71.1%) | - |
| Sep 2006 | - | $2.15 M(+26.1%) |
| Jun 2006 | - | $1.70 M(-80.6%) |
| Mar 2006 | - | $8.77 M(+1065.7%) |
| Mar 2006 | $8.77 M(+4911.7%) | - |
| Dec 2005 | - | $752.40 K(+24.7%) |
| Sep 2005 | - | $603.20 K(+37.5%) |
| Jun 2005 | - | $438.80 K(+150.7%) |
| Mar 2005 | $175.00 K(+266.9%) | $175.00 K(+61.7%) |
| Dec 2004 | - | $108.20 K(+540.2%) |
| Sep 2004 | - | $16.90 K(+238.0%) |
| Jun 2004 | - | $5000.00(-89.5%) |
| Mar 2004 | $47.70 K(+90.0%) | $47.70 K(+24.2%) |
| Dec 2003 | - | $38.40 K(+8.5%) |
| Sep 2003 | - | $35.40 K(+30.1%) |
| Jun 2003 | - | $27.20 K(+8.4%) |
| Mar 2003 | $25.10 K(+118.3%) | $25.10 K(-10.0%) |
| Dec 2002 | - | $27.90 K(-43.9%) |
| Sep 2002 | - | $49.70 K(+9.0%) |
| Jun 2002 | - | $45.60 K |
| Mar 2002 | $11.50 K | - |
FAQ
- What is Brainstorm Cell Therapeutics annual total liabilities?
- What is the all time high annual total liabilities for Brainstorm Cell Therapeutics?
- What is Brainstorm Cell Therapeutics annual total liabilities year-on-year change?
- What is Brainstorm Cell Therapeutics quarterly total liabilities?
- What is the all time high quarterly total liabilities for Brainstorm Cell Therapeutics?
- What is Brainstorm Cell Therapeutics quarterly total liabilities year-on-year change?
What is Brainstorm Cell Therapeutics annual total liabilities?
The current annual total liabilities of BCLI is $9.07 M
What is the all time high annual total liabilities for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics all-time high annual total liabilities is $18.76 M
What is Brainstorm Cell Therapeutics annual total liabilities year-on-year change?
Over the past year, BCLI annual total liabilities has changed by -$2.40 M (-20.93%)
What is Brainstorm Cell Therapeutics quarterly total liabilities?
The current quarterly total liabilities of BCLI is $8.08 M
What is the all time high quarterly total liabilities for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics all-time high quarterly total liabilities is $18.76 M
What is Brainstorm Cell Therapeutics quarterly total liabilities year-on-year change?
Over the past year, BCLI quarterly total liabilities has changed by $0.00 (0.00%)